The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KALA | -90.76% | -99.82% | -71.89% | -100% |
| S&P | +13.14% | +87.24% | +13.37% | +175% |
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Good news from the FDA translated to bad news for Kala's share price.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.13M | -103.2% |
| Market Cap | $10.74M | -59.1% |
| Market Cap / Employee | $0.28M | 0.0% |
| Employees | 38 | -11.6% |
| Net Income | -$7.56M | 15.5% |
| EBITDA | -$10.53M | -10.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $21.10M | -57.1% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.11M | -94.1% |
| Short Term Debt | $28.83M | 57.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -90.62% | -23.0% |
| Return On Invested Capital | -97.99% | -8.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10.88M | -125.9% |
| Operating Free Cash Flow | -$10.88M | -130.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.66 | 2.83 | 5.38 | -3.19 | -266.81% |
| Price to Tangible Book Value | 4.66 | 2.83 | 5.38 | -3.19 | -266.81% |
| Enterprise Value to EBITDA | -1.45 | -2.50 | -2.68 | -1.86 | 24.57% |
| Return on Equity | -431.0% | -388.3% | -576.5% | -708.3% | 185.49% |
| Total Debt | $32.25M | $32.35M | $29.93M | $29.94M | -19.16% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
